Predicting Binding to P-Glycoprotein by Flexible Receptor Docking

P-glycoprotein (P-gp) is an ATP-dependent transport protein that is selectively expressed at entry points of xenobiotics where, acting as an efflux pump, it prevents their entering sensitive organs. The protein also plays a key role in the absorption and blood-brain barrier penetration of many drugs, while its overexpression in cancer cells has been linked to multidrug resistance in tumors. The recent publication of the mouse P-gp crystal structure revealed a large and hydrophobic binding cavity with no clearly defined sub-sites that supports an “induced-fit” ligand binding model. We employed flexible receptor docking to develop a new prediction algorithm for P-gp binding specificity. We tested the ability of this method to differentiate between binders and nonbinders of P-gp using consistently measured experimental data from P-gp efflux and calcein-inhibition assays. We also subjected the model to a blind test on a series of peptidic cysteine protease inhibitors, confirming the ability to predict compounds more likely to be P-gp substrates. Finally, we used the method to predict cellular metabolites that may be P-gp substrates. Overall, our results suggest that many P-gp substrates bind deeper in the cavity than the cyclic peptide in the crystal structure and that specificity in P-gp is better understood in terms of physicochemical properties of the ligands (and the binding site), rather than being defined by specific sub-sites.

[1]  Matthew P Jacobson,et al.  Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. , 2006, Journal of the American Chemical Society.

[2]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[3]  R. Mortimer,et al.  Thyroid hormone export from cells: contribution of P-glycoprotein. , 2005, The Journal of endocrinology.

[4]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[5]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[7]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[8]  M. Hennessy,et al.  A primer on the mechanics of P-glycoprotein the multidrug transporter. , 2007, Pharmacological research.

[9]  Robert,et al.  Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. , 1989, The Journal of biological chemistry.

[10]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[11]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[12]  Alexander Golbraikh,et al.  Combinatorial QSAR Modeling of P-Glycoprotein Substrates , 2006, J. Chem. Inf. Model..

[13]  V. Ling,et al.  Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. , 1997, European journal of biochemistry.

[14]  Vijay K Gombar,et al.  Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. , 2004, Journal of pharmaceutical sciences.

[15]  Erik Evensen,et al.  A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. , 2002, Journal of medicinal chemistry.

[16]  J. Vederas,et al.  Conversion of serine to stereochemically pure .beta.-substituted .alpha.-amino acids via .beta.-lactones , 1985 .

[17]  A. Seelig A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.

[18]  I. Pastan,et al.  Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Z. Xiang,et al.  On the role of the crystal environment in determining protein side-chain conformations. , 2002, Journal of molecular biology.

[20]  E. Wang,et al.  Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. , 2000, Biochemical and biophysical research communications.

[21]  D. Clarke,et al.  Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein* , 2002, The Journal of Biological Chemistry.

[22]  P. Morgan,et al.  Role of transport proteins in drug discovery and development: a pharmaceutical perspective. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  D. Clarke,et al.  Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. , 1994, Biochemistry.

[24]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[25]  Phil Jeffrey,et al.  Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction , 2007, Journal of Pharmacology and Experimental Therapeutics.

[26]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[27]  Balázs Sarkadi,et al.  The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). , 2008, Drug discovery today.

[28]  D. Clarke,et al.  Methanethiosulfonate Derivatives of Rhodamine and Verapamil Activate Human P-glycoprotein at Different Sites* , 2003, Journal of Biological Chemistry.

[29]  J. Fletcher,et al.  ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.

[30]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[31]  D. Clarke,et al.  Simultaneous Binding of Two Different Drugs in the Binding Pocket of the Human Multidrug Resistance P-glycoprotein* , 2003, Journal of Biological Chemistry.

[32]  Miguel A. Cabrera,et al.  A topological substructural approach for the prediction of P-glycoprotein substrates. , 2006, Journal of pharmaceutical sciences.

[33]  I. Hidalgo,et al.  Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.

[34]  R. Friesner,et al.  Generalized Born Model Based on a Surface Integral Formulation , 1998 .

[35]  Matthew P. Jacobson,et al.  An atomistic model of passive membrane permeability: application to a series of FDA approved drugs , 2007, J. Comput. Aided Mol. Des..

[36]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[37]  Niu Huang,et al.  Physics-Based Scoring of Protein-Ligand Complexes: Enrichment of Known Inhibitors in Large-Scale Virtual Screening , 2006, J. Chem. Inf. Model..

[38]  M. Delaforge,et al.  Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. , 2002, Molecular pharmacology.

[39]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.

[40]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[41]  Y. Shao,et al.  Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. , 1996, Biochimica et biophysica acta.

[42]  Yiyu Cheng,et al.  Identifying P-Glycoprotein Substrates Using a Support Vector Machine Optimized by a Particle Swarm , 2007, J. Chem. Inf. Model..

[43]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[44]  Xuefeng Bruce Ling,et al.  Significance Analysis and Multiple Pharmacophore Models for Differentiating P-Glycoprotein Substrates , 2007, J. Chem. Inf. Model..

[45]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Shipman,et al.  Up-Regulation of Transporters and Enzymes by the Vitamin D Receptor Ligands, 1α,25-Dihydroxyvitamin D3 and Vitamin D Analogs, in the Caco-2 Cell Monolayer , 2009, Journal of Pharmacology and Experimental Therapeutics.

[47]  I. Poggesi,et al.  Computational models for identifying potential P-glycoprotein substrates and inhibitors. , 2006, Molecular pharmaceutics.

[48]  J. Hochman,et al.  Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. , 2002, Current drug metabolism.

[49]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[50]  M. Grever,et al.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. , 1994, Molecular pharmacology.

[51]  J. R. Somoza,et al.  Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. , 2005, Journal of medicinal chemistry.

[52]  C. Higgins,et al.  Communication between multiple drug binding sites on P-glycoprotein. , 2000, Molecular pharmacology.